In addition to TMZ, bevacizumab is approvedby the U.S. FDA for the treatment of primary and recurrent GBM; however,the outcome of some studies demonstrates the failure of bevacizumabto prolong overall survival.23 Along withoverall survival failure, it was found that the administration ofbevacizumab led to the overexpression of the receptor tyrosine kinase(RTK) c-Met, thereby causing tumor relapse.24,25. Here, MET is linked to glioblastoma.